Item 7.01 Regulation FD Disclosure.

On June 3, 2009, Synergy Pharmaceuticals, Inc. (the "Company") presented clinical data from a Phase I healthy volunteer study of SP-304, a new member of a class of investigational drugs for the treatment of constipation-predominant irritable bowel syndrome (IBS-C), and chronic idiopathic constipation, at the Digestive Disease Week annual meeting. The Company's presentation is furnished as Exhibit 99.1 to this report. The Company is also filing as Exhibit 99.2 to this Current Report on Form 8-K, an investor presentation it intends to present to various investors from time to time.

The information disclosed under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, is being furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, (the "Securities Act") except as expressly set forth in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Synergy Pharmaceuticals, Inc. Presentation of SP-304 Phase I Clinical Data.

99.2 Synergy Pharmaceuticals, Inc. Investor Presentation

---